

Figure 3. Compared with the results obtained 1 year earlier (A), technetium-99m bone scintigraphy revealed a worsening of the bone metastases (B). The accumulation of strontium-89 in a region corresponding to the observed uptake of sodium pertechnetate was confirmed 1 week after strontium-89 injection (C).




Figure 4. Bone metastases were revealed using computed tomography (arrow).

recurrences of the liver metastases were detected 18 months after TAE (May 2011). Although we proposed additional treatment by TAE or with anticancer agents, the patient refused any additional cancer treatment. At that time, the neuron-specific enolase level was normal (12.1 ng/ml). As of June 2011, the patient continued to be followed up as an out-patient, but she has not received any further treatment for hypoglycemia.

DISCUSSION

Although most patients with malignant insulinoma have lymph node or liver metastasis, there are very few reports in which malignant insulinoma metastasized to a bone (5–7). The prognosis of these patients is relatively poor with a median survival period of ~2 years (8,9).

Glycemic control is a key aspect of managing malignant insulinomas. Mild symptoms can sometimes be controlled by diet (10). Some reports have shown good control of blood glucose levels using a somatostatin analog (11–13). Somatostatin analogs such as octreotide may be helpful for the control of insulin release, but they can also suppress counter-regulatory hormones such as growth hormones, glucagons and catecholamines (10). In this situation,

somatostatin analogs can lead to the worsening of hypoglycemia (14). However, octreotide had neither a good nor a bad influence on the hypoglycemia in the patient. Diazoxide, an anti-hypertensive agent known to increase the blood sugar level, inhibits the release of insulin in pancreatic beta cells by opening ATP-sensitive potassium channels (15,16). Its side effects include edema, weight gain, renal impairment and hirsutism (10). Although our patient exhibited edema and weight gain, her hypoglycemia did not improve (Fig. 1). Some authors reported that selective TAE for liver metastases may have the greatest benefit, next to diazoxide (17–22). However, in the present patient, TAE was not effective for glycemic control because unregulated secretion of insulin was mainly caused by the bone metastases.

Concerning other treatment options, De Jong et al. (23) reported that radiolabeled somatostatin analogs, such as [(90)Y-DOTA, Tyr(3)] octreotide and [(177)Lu-DOTA, Tyr(3)] octreotide, are promising treatment modalities for patients with neuroendocrine tumors. However, these radionuclide therapies are not available in Japan. Antiproliferative agents such as streptozotocin, sunitinib and everolimus are also good treatment options (24–26). However, these agents are not covered by the national health insurance in Japan.

^{89}Sr decays by beta emission, with a maximum beta energy of 1.46 MeV, an average soft-tissue penetration of 2.4 mm and a half-life of 50.6 days. After administration, ^{89}Sr is taken up into the mineral matrix of the bone and is selectively concentrated in areas of osteoblastic activity in disease-affected bone, with a biological behavior resembling that of calcium (27). The biodistribution of ^{89}Sr parallels technetium bone-scanning agents (28,29). Pain relief is often obtained 14–21 days after injection (30). Thrombocytopenia and neutropenia are the most common toxic effects, but these effects are generally mild and reversible. Because ^{89}Sr is eliminated mainly via the kidneys, patients are advised to carefully dispose of urine for the first 10 days after administration (27).

The biological mechanism by which ^{89}Sr mediates pain palliation remains unclear. In some basic studies, two possible mechanisms of pain palliation by ^{89}Sr have been proposed (31). One of these mechanisms is a direct radiotoxic effect on the cancer cells caused by the beta-ray emission

from ⁸⁹Sr. The second mechanism is an indirect action through prostaglandin E2 (PGE2) and interleukin-6 (IL-6) produced by cells in response to ⁸⁹Sr. PGE2 and IL-6 are known as potent biochemical modifiers of bone turnover. In the patient, the mechanism of improved hypoglycemia was thought to be a direct radiotoxic effect of ⁸⁹Sr on the cancer cells. The tumoricidal effect of ⁸⁹Sr on metastatic bone tumors has been reported previously. Dafermou et al. (32) reported that ⁸⁹Sr therapy resulted in the scintigraphic regression of bone metastases in patients with painful bone metastases from prostate cancer. In addition, Porter et al. (33) reported the reduction of tumor markers, including prostate specific antigen and alkaline phosphatase in the ⁸⁹Sr therapy of painful bone metastases from prostate cancer. Suzawa et al. (34) reported a case of the complete regression of multiple painful bone metastases from hepatocellular carcinoma after the administration of ⁸⁹Sr.

In our case, although obvious regression of bone metastases was not detected by the subsequent computed tomography image (Fig. 4), the alkaline phosphatase level decreased (Fig. 1). Because bone scintigraphy was not useful for strict response evaluation, we did not perform it immediately after the strontium-89 injection in this case. Successful pain relief was achieved. Although the intractable hypoglycemia was resistant to all other treatments, it was improved by ⁸⁹Sr therapy. Though ⁸⁹Sr therapy is generally indicated for patients with multiple painful bone metastases, in this case, it was also useful as a means of arresting tumor growth and inhibiting tumor activity. To our knowledge, this report is the first to provide evidence that ⁸⁹Sr can be useful in controlling intractable hypoglycemia in malignant insulinoma with bone metastases.

CONCLUSION

We experienced a case of malignant insulinoma and bone metastases in which intractable hypoglycemia was successfully controlled by using radiopharmaceutical therapy with ⁸⁹Sr.

Conflict of interest statement

Dr Chigusa Morizane received lecture fee from Novartis Pharma Co., Ltd.

References

1. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinoma: current issues and trends. *Hepatobiliary Pancreat Dis Int* 2010;9:234–41.
2. Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. *Cancer* 2005;104:264–72.
3. Yamaguchi K. Pain control for bone metastasis using radioactive strontium. *Gan To Kagaku Ryoho* 2010;37:1868–71.
4. Ackery D, Yardley J. Radionuclide-targeted therapy for the management of metastatic bone pain. *Semin Oncol* 1993;20(Suppl. 2):27–31.

5. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM. Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. *Surgery* 2002;132:976–82.
6. Hesdorffer CS, Stoopler M, Javitch J. Aggressive insulinoma with bone metastases. *Am J Clin Oncol* 1989;12:498–501.
7. Imamura M, Miyashita E, Miyagawa K, Matsuno S, Sato T. Malignant insulinoma with metastasis to gallbladder and bone, accompanied by past history of peptic ulcer and hyperthyroidism. *Dig Dis Sci* 1987;32:1319–24.
8. Danforth DN, Jr, Gorden P, Brennan MF. Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery. *Surgery* 1984;96:1027–37.
9. Grama D, Eriksson B, Mårtensson H. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. *World J Surg* 1992;16:632–9.
10. DeVita VT, Jr, Lawrence TS, Rosenberg SA. Chapter 111: Pancreatic neuroendocrine tumors. *Cancer of the Endocrine system/Practice of Oncology DeVita, Hellman, and Rosenberg's Cancer Principles & Practice. 9th edn.* Lippincott: Williams & Wilkins 2011;1489–502.
11. Stefanini P, Carboni M, Patrassi N, Basoli A. Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. *Surgery* 1974;75:597–609.
12. Baldelli R, Ettore G, Vennarecci G, et al. Malignant insulinoma presenting as metastatic liver tumor. Case report and review of the literature. *J Exp Clin Cancer Res* 2007;26:603–7.
13. Vezzosi D, Bennet A, Courbon F, Caron P. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. *Clin Endocrinol (Oxf)* 2008;68:904–11.
14. Stehouwer CD, Lems WF, Fischer HR, Hackeng WH, Naafs MA. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analogue octreotide (Sandostatin). *Acta Endocrinol (Copenh)* 1989;121:34–40.
15. Fajans SS, Floyd JC, Jr, Knopf RF, Rull J, Guntsche EM, Conn JW. Benzothiadiazine suppression of insulin release from normal and abnormal islet tissue in man. *J Clin Invest* 1966;45:481–92.
16. Fajans SS, Floyd JC, Jr, Thiffault CA, Knopf RF, Harrison TS, Conn JW. Further studies on diazoxide suppression of insulin release from abnormal and normal islet tissue in man. *Ann N Y Acad Sci* 1968;150:261–80.
17. Nesović M, Cirić J, Radojković S, Zarković M, Durović M. Improvement of metastatic endocrine tumors of the pancreas by hepatic artery chemoembolization. *J Endocrinol Invest* 1992;15:543–7.
18. Winkelbauer FW, Nierderle B, Graf O, et al. Malignant insulinoma: permanent hepatic artery embolization of liver metastases—preliminary results. *Cardiovasc Intervent Radiol* 1995;18:353–9.
19. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. *J Vasc Interv Radiol* 1999;10:397–403.
20. Kim YH, Ajani JA, Carrasco CH, et al. Selective hepatic arterial chemoembolization for liver metastases in patients with carcinoid tumor or islet cell carcinoma. *Cancer Invest* 1999;17:474–8.
21. Moscetti L, Saltarelli R, Giuliani R, Fornarini G, Bezzi M, Cortesi E. Intra-arterial liver chemotherapy and hormone therapy in malignant insulinoma: case report and review of the literature. *Tumori* 2000;86:475–9.
22. Hayashi M, Takaichi K, Kariya T, et al. Malignant insulinoma which expressed a unique creatine kinase isoenzyme: clinical value of arterial embolization as a palliative therapy. *Intern Med* 2000;39:474–7.
23. De Jong M, Valkema R, Jamar F, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. *Semin Nucl Med* 2002;32:133–40.
24. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. *N Engl J Med* 1992;326:519–23.
25. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:501–13.
26. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. *N Engl J Med* 2011;364:514–23.
27. Lin A, Ray ME. Targeted and systemic radiotherapy in the treatment of bone metastasis. *Cancer Metastasis Rev* 2006;25:669–75.

28. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. *Eur J Nucl Med* 1986;12:447–54.
29. Blake GM, Zivanovic MA, Blaquiére RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. *J Nucl Med* 1988;29:549–57.
30. Lewington VJ, McEwan AJ, Ackery DM, et al. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. *Eur J Cancer* 1991;27:954–8.
31. Davis J, Pither RJ. Biochemical responses in cultured cells following exposure to (89)SrCl(2):potential relevance to the mechanism of action in pain palliation. *Eur J Cancer* 2001;37:2464–9.
32. Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. *Eur J Nucl Med* 2001;28:788–98.
33. Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. *Int J Radiat Oncol Biol Phys* 1993;25:805–13.
34. Suzawa N, Yamakado K, Takaki H, Nakatsuka A, Takeda K. Complete regression of multiple painful bone metastases from hepatocellular carcinoma after administration of strontium-89 chloride. *Ann Nucl Med* 2010;24:617–20.

Effect of chemotherapy on survival after whole brain radiation therapy for brain metastases: a single-center retrospective analysis

Hiroshi Mayahara · Minako Sumi · Yoshinori Ito · Syuhei Sekii ·
Kana Takahashi · Kouji Inaba · Yuuki Kuroda · Naoya Murakami ·
Madoka Morota · Jun Itami

Received: 10 January 2012 / Accepted: 5 March 2012
© Springer-Verlag 2012

Abstract

Background and purpose Whether chemotherapy for systemic disease affects survival of patients with brain metastases or not has not been elucidated before. We performed comprehensive analysis of patients with newly-diagnosed brain metastases primarily treated with whole brain radiation therapy (WBRT) alone.

Materials and methods Data from 134 patients with newly-diagnosed brain metastases primarily treated with WBRT from 2007 to 2008 was retrospectively reviewed. Univariate and multivariate analyses were performed to identify significant prognostic factors.

Results Median survival time (MST) of this cohort from the start of WBRT was 5.7 months. MST of patients with RPA Class 1, 2 and 3 were 10.3, 7.8 and 2.2 months, respectively. Multivariate analysis revealed that Karnofsky performance status (≥ 70 , $p < 0.0001$), gender (female, $p < 0.0001$), activity of extracranial disease (stable, $p = 0.015$), time to develop brain metastasis (< 3 months, $p = 0.042$) and use of chemotherapy after WBRT (multiple regimens, $p < 0.0001$) were independent prognostic factors for better survival.

Conclusions Systemic chemotherapy for chemo-responsive cancer prolongs survival despite the presence of treated brain metastases. Irradiated brain metastases will lose their prognostic significance in a large number of

patients. Systemic chemotherapy will be a treatment of choice for patients who have systemic disease after WBRT for brain metastases. These results should be validated in the future prospective clinical trials.

Keywords Brain metastasis · Brain metastases · Radiation therapy · Whole brain radiation therapy · Chemotherapy · Prognostic factors

Introduction

Brain metastasis affects 20–40 % of cancer patients (Soffietti et al. 2002). Brain metastasis is one of the major causes of morbidity in cancer patients. The prognosis of patients with brain metastasis is generally poor with a median survival time (MST) of 1–2 months with corticosteroids only (Weissman 1988; Lagerwaard et al. 1999).

The route of metastatic dissemination to the brain is often hematogenous, therefore, the entire brain can be seeded with micrometastatic focus. Traditionally, whole brain radiation therapy (WBRT) has been regarded as the standard treatment for patients with brain metastasis. Overall survival of the patients after WBRT ranges 3–6 months (Lagerwaard et al. 1999; Gaspar et al. 2010; Tsao et al. 2005). Various dose/fractionation schedules of WBRT were tested in clinical studies, which resulted in no significant difference in median survival time after WBRT (Tsao et al. 2005; Gaspar et al. 2010).

Recently, significant progress has been made for a subset of patients with single or few brain metastases and well controlled systemic disease. Surgical resection or stereotactic radiosurgery (SRS) combined with WBRT significantly prolonged survival (Patchell et al. 1990; Vecht et al. 1993; Andrews et al. 2004). Median survival of

This study was presented in part at the 53rd Annual Meeting of the American Society for Radiation Oncology in Miami, October 2–6, 2011.

H. Mayahara (✉) · M. Sumi · Y. Ito · S. Sekii · K. Takahashi ·
K. Inaba · Y. Kuroda · N. Murakami · M. Morota · J. Itami
Division of Radiation Oncology, National Cancer Center Hospital,
5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
e-mail: hmayahar@ncc.go.jp

patients who received these aggressive therapies ranges 7–10 months. Unfortunately, patients who entered into these clinical trials represent only a small minority of the patients with brain metastases. For the majority of patients with multiple brain metastases and uncontrolled systemic disease, only WBRT is the standard treatment of choice.

The role of chemotherapy in brain metastasis has been limited because of the concern about the activity of chemotherapeutic agent to cross the blood–brain barrier (BBB). Recently, the activity of chemotherapy in brain metastasis is highlighted (Robinet et al. 2001; Walbert and Gilbert 2009; Mehta et al. 2010). Concurrent chemoradiation therapies with BBB permeable agents, such as Temozolamide or topotecan are currently under investigation in prospective clinical trials. Some investigators suggested that the permeability of BBB can alter after fractionated radiotherapy for brain metastasis (Yuan et al. 2006; Wilson et al. 2009). However, whether the use of chemotherapy affects survival of the patients with brain metastasis or not has not been elucidated before.

The primary aim of this study was to perform comprehensive analysis of 134 consecutive patients with newly-diagnosed brain metastases primarily treated by WBRT alone in a single institution. The secondary aim was to define independent prognostic factors associated with longer survival after WBRT. The final aim was to investigate the prognostic value of chemotherapy on survival after WBRT in patients with brain metastases.

Materials and methods

Patient characteristics

The database of patients who underwent radiotherapy for brain metastases at our institution was reviewed. A total of 264 patients were treated with WBRT between 2007 and 2008. Of these, 23 patients received WBRT as a salvage therapy after SRS. Another 39 patients received WBRT as an adjuvant therapy after resection of metastatic brain tumor. Forty-seven patients were metastases from radio-sensitive primary tumor such as leukemia, lymphoma or small cell carcinoma. Excluding these patients, we reviewed the medical records of 155 patients with newly diagnosed brain metastases treated with WBRT as a primary therapy. Of these, 19 patients presented with symptoms or radiographic findings of leptomeningeal metastasis. We excluded these patients with leptomeningeal metastasis because they are known to have extremely limited survival. Two patients were ineligible for evaluation because of allergy to contrast media. Finally, a group of 134 patients were subjected to extensive analysis. The clinical and image interpretation data from these patients

Table 1 Distribution of baseline patient and tumor characteristics

Parameters	n	%	Parameters	n	%
Median age (years)	60		Extracranial distant metastases		
Gender			Absent	11	8
Male	69	51	Stable	16	12
Female	65	49	Progressive	107	80
Karnofsky performance status (KPS)			Activity of extracranial tumor		
100–90	46	34	Absent/stable	20	15
80–70	49	37	Progressive	114	85
60–50	29	22	Time to diagnosis of brain metastasis		
40–0	10	7	<3 months	21	16
Neurologic status			3–12 months	33	25
0	45	34	1–2 years	22	16
1	27	20	≥2 years	58	43
2	34	25	Type of the diagnostic brain image		
3	21	16	MRI	106	79
4	7	5	CT	28	21
RPA criteria			Number of brain metastases		
Class 1	5	4	1–4	40	30
Class 2	91	68	5–10	39	29
Class 3	38	28	11–24	29	22
Site of primary tumor			≥25	26	19
Lung	75	56	Size of the largest lesion		
Breast	27	20	≤10	31	23
Upper gastrointestinal tract	11	8	11–20	46	34
Colorectum	10	8	21–30	34	25
Genitourinary tract	5	4	>30	23	17
Others	6	5	Chemotherapeutic regimens before WBRT		
Histological type			None	22	16
Adenocarcinoma	114	85	Single	28	21
Squamous cell carcinoma	9	7	Multiple	84	63
Others	11	8	Chemotherapeutic regimens after WBRT		
Primary tumor status			None	70	52
Absent	57	42	Single	31	23
Stable	25	19	Multiple	33	25
Progressive	52	39	Molecular targeted therapy after WBRT (>1 month)		
			No	100	74
			Yes	34	26

RPA recursive partitioning analysis, MRI magnetic resonance imaging, CT computed tomography, WBRT whole brain radiation therapy

were entered into database in December 2010. Distribution of baseline patient and tumor characteristics is shown in Table 1.

Imaging studies

Diagnosis of brain metastases was performed mainly with magnetic resonance images (MRI). In our institute, all patients with lung cancer routinely undergo brain imaging for initial staging or scheduled follow-up. Patients with other solid tumors underwent brain imaging when brain metastasis is clinically suspected. In this study, initial diagnostic brain images included MRI in 106 patients (79 %) and CT in 28 patients (21 %). Radiological features assessed included number, maximum tumor diameter and location. For follow-up brain images, change in size of the tumors and presence of new metastases were recorded. At least 20 % increase in diameter of the each preexisted tumor before WBRT, taking as reference on the smallest diameter after WBRT, was defined as local progression.

Treatment strategy

Treatment strategy for brain metastasis at our institution was previously described elsewhere (Narita and Shibui 2009; Hashimoto et al. 2011). Patients who received WBRT alone as a primary treatment for brain metastases were subjected for this study. Patients with brain metastases generally have extracranial systemic disease. After WBRT, patients with known systemic disease were indicated to start or continue chemotherapy if they still had active chemotherapeutic regimen with sufficient organ function and with Karnofsky performance status (KPS) of 70 or more. Salvage SRS was considered for recurrent brain metastases after WBRT. Some patients with known chemo-sensitive tumor continued palliative chemotherapy for recurrent brain metastases.

Consent for the treatment was obtained from each patient after the sufficient explanation of potential risks of treatment. All the patients provided written informed consent. Our institutional review board has approved this study.

Whole brain radiation therapy

One hundred and thirty-four patients were intended to receive WBRT. Of these, 128 patients were delivered to a dose of 30 Gy in 10 fractions. Another 3 patients were delivered to 37.5 Gy in 15 fractions, whereas one patient was delivered to 20 Gy in 5 fractions. Two patients discontinued irradiation course because of the deterioration of general condition at a dose of 12 and 24 Gy, respectively.

Retrospective analysis

All the medical charts of the eligible patients were reviewed. Information on potential prognostic factors (age,

gender, KPS, neurologic status, site of primary tumor, primary tumor status, activity of extracranial distant metastases, time to develop brain metastasis, number of brain metastases, size of the largest lesion, use of chemotherapy before or after WBRT) was collected.

Initial neurological function was classified into 4 categories (No symptoms: grade 0, Minor symptoms; fully active without assistance: grade 1, Moderate symptoms; fully active but requires assistance: grade 2, Moderate symptoms; less than fully active: grade 3, Severe symptoms; totally inactive: grade 4). Radiation Therapy Oncology Group's (RTOG) recursive partitioning analysis (RPA) classes were coded into 3 categories as follows: Class 1: Patients with KPS \geq 70, <65 years of age with controlled primary and no extracranial metastases; Class 3: KPS < 70; Class 2: all the others (Gaspar et al. 1997).

For the evaluation of extracranial disease status, if there were no evidence of residual tumor after therapy, the activity was coded as "absent". If any tumor existed and there is no increase in size of the tumor for more than 6 months, the activity was coded as "stable". A continuous use of same chemotherapeutic regimen didn't impair the coding of "stable". If any tumor existed with any situation other than "stable", the activity was coded as "progressive".

Patients whose brain metastases were detected at the same time or soon after the diagnosis of primary tumor (so-called "synchronous" brain metastasis) may have different prognosis. We defined "synchronous" brain metastasis as those detected at the same time or detected within 3 months of the initial diagnosis of primary tumor.

For the analysis of prognostic effect of chemotherapy before or after WBRT, three different cohorts were defined: none, single regimen and multiple regimens. If a patient received two or more different types of chemotherapeutic regimens, the status was coded as multiple regimens. Any type of hormonal therapy was regarded as a single regimen. The status of the use of molecular targeted therapy was defined as "yes", if a patient continued to receive a specific regimen for more than 1 month.

Statistical analysis

Overall survival from the start of WBRT was calculated with the Kaplan–Meier method. For univariate and multivariate analysis, all the variables were dichotomized according to the clinical relevance from previous literature. Univariate analyses were performed by using log-rank test. Possible confounded variables were excluded from multivariate analysis. A Cox's proportional hazards model was developed to identify significant factors influencing survival after WBRT. All the tests of hypotheses were

conducted at the alpha level of 0.05 with a 95 % confidence interval. All the statistical analyses were performed by using SPSS Statistics version 17.0 (SAS Institute, Tokyo, Japan).

Results

Outcomes for the entire group

Median survival time (MST) for the entire patients from the start of WBRT was 5.7 months. The 6 months, 1- and 2-year survival rate were 43, 28 and 12 %, respectively. MST of the patients with RTOG's RPA Class 1 ($n = 5$), 2 ($n = 91$) and 3 ($n = 38$) were 10.3, 7.8 and 2.2 months, respectively (Fig. 1). Median intracranial progression-free survival (PFS) were 4.7 months, with 6 months, 1- and 2-year PFS of 35, 14 and 4 %, respectively. A total of 49 patients developed intracranial recurrence after WBRT. The sites of first recurrence after WBRT were as follows: local only (regrowth of preexisted tumors): 25 (51 %); new metastasis only: 10 (20 %); both of local and new metastasis: 12 (24 %); and leptomeningeal dissemination: 2 (4 %). Median local progression-free duration and median intracranial new metastasis-free duration for the entire patients were 9.7 and 18.0 months, respectively. At the time of analysis, 5 patients were alive with disease. The causes of death were identified in 118 patients. Of these, 38 patients (32 %) were due to intracranial tumor progression, whereas 76 patients (64 %) were due to systemic disease. Four patients (3 %) died from intercurrent disease. None had died directly from toxicity of WBRT.




Fig. 1 Kaplan–Meier survival curve for overall survival by RPA criteria

Factors influencing survival after WBRT: univariate and multivariate analyses

Univariate analysis was performed on 12 different variables to evaluate their potential value on survival after WBRT. Univariate analyses identified 9 variables which significantly associated with good prognosis (Table 2).

Multivariate analysis was performed on 9 independent variables. Table 3 summarizes the result of the multivariate analysis for survival after WBRT. Multivariate analysis revealed that KPS (≥ 70 vs. 70, hazard rate (HR): 2.540, $p < 0.0001$), gender (female vs. male, HR: 2.293, $p < 0.0001$), activity of extracranial disease (absent/stable vs. progressive, HR: 2.134, $p = 0.015$), time to develop brain metastasis (< 3 vs. ≥ 3 months, HR: 1.926, $p = 0.042$), and use of chemotherapy after WBRT (multiple vs. none/single regimens, HR: 3.406, $p < 0.0001$) were independent prognostic factors for overall survival.

Survivals depending on chemotherapy after WBRT

After WBRT, only two patients had no evidence of extracranial tumor. The two patients didn't receive further chemotherapy until disease progression. Another 132 patient had known extracranial tumor including primary, nodal or distant sites. They were indicated to start or continue chemotherapy when it was clinically applicable. A total of 64 patients with extracranial systemic disease underwent chemotherapy after WBRT. Thirty-one patients (23 %) received only a single chemotherapeutic regime, and 33 patients (25 %) received multiple regimens. Figure 2 shows the survival curve by the use of chemotherapy after WBRT. The MST of the patients who received none, single and multiple regimens after WBRT were 3.3, 7.5 and 16.4 months, respectively ($p < 0.0001$). The use of multiple chemotherapeutic regimens after WBRT was found to be associated with better survival after WBRT in multivariate analysis ($p < 0.0001$). Among 95 patients with pre-irradiation KPS ≥ 70 , 59 patients (62 %) received chemotherapy, whereas 5 patients (13 %) with KPS < 70 received chemotherapy. Among patients with KPS ≥ 70 , the MST of the patients who received none, single and multiple regimens after WBRT were 4.5, 7.9 and 16.4 months, respectively ($p < 0.0001$). Overall, 95 % of the patients included in this study received chemotherapy either before or after WBRT.

The effect of molecular-targeted therapy after WBRT

A total of 34 patients (25 %) received molecular-targeted therapy after WBRT for 1 month or more. Of these patients, the sites of primary disease were lung in 28, breast

Table 2 Results of univariate analyses for survival after WBRT

Parameters	<i>n</i>	Median survival time (months)	6-months survival (%)	1-year survival (%)	2-year survival (%)	<i>p</i> value
Overall patients	134	5.7	43	28	12	–
Age						
<65	87	7.4	54	31	13	
≥65	47	4.9	38	22	11	0.31
Gender						
Male	69	4.5	32	17	6	
Female	65	9.1	66	40	20	0.0009
Karnofsky performance status						
≥70	95	7.9	62	39	17	
<70	39	2.2	15	3	0	<0.0001
Neurologic status						
0–1	72	7.9	58	44	22	
2–4	62	4.5	36	1	0	<0.0001
RPA criteria						
Class 1–2	96	7.9	61	37	18	
Class 3	38	2.2	16	5	0	<0.0001
Site of primary tumor						
Lung	75	7.4	55	39	21	
Others	59	4.5	39	14	2	0.001
Activity of extracranial tumor						
Absent/stable	20	9.1	60	40	25	
Progressive	114	5.2	46	26	10	0.015
Time to develop brain metastasis						
<3 months	21	16.9	75	65	40	
≥3 months	113	5.2	43	21	7	0.002
Number of brain metastasis						
1–4	40	5.1	39	21	10	
≥5	94	6.2	52	31	13	0.53
Size of the largest lesion						
<20 mm	69	7.4	53	36	16	
≥20 mm	65	5.1	42	20	8	0.11
Chemotherapeutic regimens before WBRT						
None/single	50	7.2	52	42	20	
Multiple	84	5.2	46	19	8	0.019
Chemotherapeutic regimens after WBRT						
None/single	101	4.0	33	13	4	
Multiple	33	16.4	94	73	36	<0.0001

RPA recursive partitioning analysis, WBRT whole brain radiotherapy

in 5 and kidney in 1. All of the histological diagnoses of lung primary patients were adenocarcinoma. Twenty-seven lung primary patients received epidermal growth factor

receptor-tyrosine kinase inhibitor (EGFR-TKI) for a median duration of 7 months. Figure 3 shows the survival curve by the use of molecular-targeted therapy after

Table 3 Results of multivariate analysis for survival after WBRT

Variables	Factors	Hazard rate (95 % CI)	<i>p</i> value
Karnofsky performance status	≥70 versus <70	2.540 (1.627–3.966)	<0.0001
Gender	Female versus male	2.293 (1.541–3.412)	<0.0001
Extracranial disease status	Absent/stable versus progressive	2.134 (1.160–3.928)	0.015
Time to develop brain metastasis	<3 versus ≥3 months	1.926 (1.025–3.620)	0.042
Number of chemotherapeutic regimens after WBRT	Multiple regimens versus none/single regimen	3.406 (2.013–5.761)	<0.0001

CI confidence interval, WBRT whole brain radiation therapy




Fig. 2 Kaplan–Meier overall survival curve by the use of chemotherapeutic regimen after WBRT




Fig. 3 Kaplan–Meier overall survival curve by the use of molecular-targeted therapy after WBRT

WBRT. The MST of the patients who received molecular-targeted therapy after WBRT was significantly longer than that of those who did not (16.4 vs. 4.0 months, $p < 0.0001$).

Discussion

Significant progress has been made over the last decades for a subset of patients with single or few brain metastases and well controlled systemic disease. In prospective randomized clinical trials, surgical resection or SRS combined with WBRT significantly prolonged survival in selected patients with single or few brain metastases (Patchell et al. 1990; Vecht et al. 1993; Andrews et al. 2004). MST of these patients who received combined therapy ranges 7–10 months. SRS alone in patients with one or few brain metastases was comparable to SRS combined with WBRT at least in terms of overall survival, with a MST of 8 months (Aoyama et al. 2006). Unfortunately, the patients who entered into these clinical trials represent only a small minority of patients with brain metastases. In clinical practice, it remains unclear whether these aggressive therapies have sufficient benefit for the majority of patients with uncontrolled systemic disease or numerous brain metastases. Currently, only WBRT is the standard treatment of choice for these patients. The indication of SRS for patients with brain metastases in clinical practice continues to be a matter of debate.

Various prospective and retrospective studies have shown that the treatment modality is the first most important prognostic factor on long-term survival, although the effect of patient selection bias is inevitable (Andrews et al. 2004; Lagerwaard et al. 1999; Patchell et al. 1990). To minimize the selection bias, we investigated only patients primarily treated with WBRT alone in this study. Numerous studies on prognostic factors in patients with brain metastases have been published previously. The results of this study re-confirmed the value of established prognostic factors reported in the literature. Multivariate analysis showed that good KPS, stable extracranial disease and female gender were independent predictors of better survival after WBRT, in line with previous literatures (Lagerwaard et al. 1999; Patchell et al. 1990; Aoyama et al. 2006; Gaspar et al. 1997; Swinson and William 2008). Dose these pretreatment characteristics fully determine the prognosis of patients with brain metastases?

Performance status is regarded as the second most important prognostic factor in patient's characteristics (Lagerwaard et al. 1999; Aoyama et al. 2006; Gaspar et al. 1997; Fleckenstein et al. 2004; 20). Generally, patients with low KPS are not indicated for aggressive therapy other than WBRT alone. In this study, the MST of the patients with KPS < 70 was only 2.2 months. The Performance status of the patients with brain metastases frequently deteriorated by extended intracranial disease. Additionally, patients with very low performance status were not indicated for further chemotherapy despite the existence of systemic disease. In this study, only 5 patients (13 %) with pre-treatment KPS < 70 received chemotherapy after WBRT. We conclude that poor survival time of the patients with low KPS is due to the systematic disease progression, as well as intracranial disease progression.

In line with our study, activity of extracranial primary disease is the third most important prognostic factor reported in the literature (Lagerwaard et al. 1999; Aoyama et al. 2006; Fleckenstein et al. 2004; 20). These finding suggests that survival of patients with brain metastases is in a large part, regulated by the extracranial status. Seventy-six patients (64 %) included in this study died due to systemic disease. This percentage is comparable to the reports of prospective clinical trials with SRS alone or SRS + WBRT for single or fewer numbers of brain metastases with well controlled systemic disease (Sneed et al. 1999; Andrews et al. 2004; Aoyama et al. 2006). This result highlights the modest effectiveness of WBRT on brain metastases. WBRT alone have adequate efficacy to avoid neurologic death for about two-thirds of patients with brain metastases. If we consider the high morbidity rate from systemic disease after WBRT, chemotherapy is the primary therapeutic approach for the control of extracranial disease. Therefore, systemic chemotherapy for chemoresponsive cancer prolongs survival despite the presence of treated brain metastases. Irradiated brain metastases will lose their prognostic significance in a large number of patients.

The role of chemotherapy in brain metastasis itself has been limited. Although there is some breakdown of blood-brain barrier (BBB) around brain metastases, the concentrations of most of the chemotherapeutic agents are still very limited within the lesion (Gerstner and Fine 2007). However, some chemotherapeutic agents are known to have activity of crossing BBB. Temozolomide (TMZ) is a third generation alkylating agent, and it can cross the BBB because of its small size and lipophilic properties (Ostermann et al. 2004). Some clinical trials suggest that single agent TMZ has some activity in patients with recurrent brain metastases (Christodoulou et al. 2001; Siena et al. 2010). Several Phase II clinical trials of TMZ combined with WBRT were performed with promising results

(Antonadou et al. 2002; Addeo et al. 2008). These trials proved improved response rate and neurologic function with addition of TMZ to WBRT. A phase III clinical trial of WBRT plus SRS with or without TMZ or Erlotinib in patients with brain metastases is now ongoing (Clinical-Trials.gov identifier: NCT00096265). Patients with 1–3 brain metastases from histologically confirmed non-small cell lung cancer, well circumscribed, maximum diameter of 4 cm or less, no metastasis within 10 mm of the optic apparatus, no metastasis in the brain stem and stable extracranial metastases are enrolled. Patients are randomized to three groups: Arm 1: WBRT + SRS, Arm 2: WBRT + SRS + TMZ, Arm 3: WBRT + SRS + erlotinib. Patients in Arm 2 and 3 begin TMZ or erlotinib on the first day of WBRT and continue up to 6 months. The primary endpoint is overall survival, and secondary endpoint includes time to CNS progression, performance status at 6 months, steroid dependence at 6 months, cause of death and effect of non-protocol chemotherapy.

Topotecan is a semi-synthetic analogue of the alkaloid camptothecin, which selectively inhibits topoisomerase I. Topotecan crosses the BBB, because of its low protein binding property (Baker et al. 1996). Single agent topotecan has positive activity in patients with brain metastases from small cell lung cancer (Korfel et al. 2002). A phase III multicentric clinical trial of topotecan and WBRT for patients with brain metastases from lung cancer was planned, however, was terminated because of low patient accrual (Neuhaus et al. 2009). This trial failed to show clear benefit of adding topotecan to WBRT. Another multicentric phase III clinical trial is ongoing (Clinical-Trials.gov identifier: NCT00390806). Patients with at least one brain metastasis from non-small cell lung cancer, who have received previous chemotherapy are enrolled. Patients are randomized to two groups: experimental arm: topotecan + WBRT, control arm: WBRT alone. The primary endpoint is overall survival, secondary endpoint includes response rate, time to response, time to progression, brain tumor symptom, safety and tolerability. We think that these clinical trials for brain metastasis should evaluate the effect of non-protocol chemotherapy on survival. In the next 5 years, the results of these phase III, multicentric clinical trials will become available to further define the role of these chemotherapeutic agents when combined with WBRT and SRS, or both.

Some investigators suggest that the permeability of BBB in brain tumors can alter during or ever after fractionated radiotherapy (Yuan et al. 2006; Wilson et al. 2009; Cao et al. 2005). After irradiation, the BBB may be partially disrupted so that some chemotherapeutic agents can reach a therapeutic level in the metastatic tumors. This is another explanation of the value of systemic chemotherapy after WBRT. In fact, subset analysis of this study showed that

the use of chemotherapy after WBRT was also an independent prognostic factor predicting longer local tumor progression-free duration (data not shown). We believe that some brain metastases become sensitive to chemotherapy after irradiation. Chemo-sensitivity of brain metastases can affect the survival of a part of patients with treated brain metastases. Therefore, systemic chemotherapy will be a treatment of choice for those who have systemic disease with irradiated brain metastases. If a patient have a plan of definitive chemotherapy for primary disease after the treatment of brain metastases, such patient can be a good candidate for more aggressive therapy for brain metastases.

Another topic of debate is whether molecular-targeted therapy has a significant role on brain metastasis or not. Some investigators advocated that EGFR-TKI has promising activity on previously untreated brain metastases from lung adenocarcinoma (Wu et al. 2007; Kim et al. 2009; Katayama et al. 2009). Another investigator reported activity of trastuzumab on brain metastasis from HER2-overexpressing breast cancer (Park et al. 2009). In this study, the MST of the patients who received molecular-targeted therapy after WBRT was significantly longer than that of those who did not. In the subset analysis of this study, use of molecular-targeted therapy after WBRT was also a significant predictor of longer local progression-free duration (data not shown). We believe that molecular-targeted therapy could have some activity on the local control of some brain metastases.

Patients with “synchronous” brain metastasis survived significantly longer than “metachronous” brain metastasis patients in this study. Short time to develop brain metastasis was marginally independent prognostic factor in multivariate analysis. This is in line with a literature of surgical removal or SRS for brain metastasis (Flannery et al. 2008; Bonnette et al. 2001; Hu et al. 2006). It is easy to assume that systemic disease of patients with “synchronous” brain metastasis would more likely to respond to the following chemotherapy. The “synchronous” brain metastasis may be more sensitive to radiotherapy, when compared to brain metastasis emerged after repeated chemotherapies. Also in agreement with some literature (Lagerwaard et al. 1999; Swinson and William 2008), female patients survived significantly longer than male patients. In particular, the prognosis of female patients with brain metastasis from lung primary has reported to be significantly better than that of male patients (Lagerwaard et al. 1999; Sánchez de Cos et al. 2009). We should further continue to investigate these clinical characteristics of brain metastases.

We acknowledge that the present study had certain limitations because of its retrospective nature. First, the results of this study might be highly influenced by patient’s selection bias. Patients with brain metastases which well

responded to WBRT may have more opportunity for receiving multiple chemotherapy after WBRT. Second, our cohort should deviate to patients with numerous brain metastases with uncontrolled systemic disease. Because we included only patients with brain metastases primarily treated by WBRT alone, patients with poor prognosis should be negatively selected for this study. Currently, we are investigating the patients with one or few brain metastases primarily treated by SRS alone, and it will be described in another report. Actual prognostic value of chemotherapy on survival after WBRT for brain metastases should be validated in future prospective clinical trials.

Conclusions

In addition to the confirmed prognostic factors previously reported in the literature, the use of multiple chemotherapeutic regimens after WBRT was associated with better survival. Systemic chemotherapy for chemo-responsive cancer prolongs survival despite the presence of treated brain metastases. Irradiated brain metastases will lose their prognostic significance in a large number of patients. Systemic chemotherapy will be a treatment of choice for patients who have systemic disease after WBRT for brain metastases. These results should be validated in future prospective clinical trials.

Conflict of interest None.

References

- Addeo R, De Rosa C, Faiola V et al (2008) Phase 2 trial of temozolomide using protracted low-dose and whole-brain radiotherapy for non-small cell lung cancer and breast cancer patients with brain metastases. *Cancer* 113:2524–2531
- Andrews DW, Scott CB, Sperduto PW et al (2004) Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. *Lancet* 363:1665–1672
- Antonadou D, Paraskevaidis M, Sarris G et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. *J Clin Oncol* 20:3644–3650
- Aoyama H, Shirato H, Tago M et al (2006) Stereotactic radiosurgery plus whole-brain radiation therapy vs. stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 295:2483–2491
- Baker SD, Heideman RL, Crom WR et al (1996) Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. *Cancer Chemother Pharmacol* 37:195–202
- Bonnette P, Puyo P, Gabriel C et al (2001) Surgical management of non-small cell lung cancer with synchronous brain metastases. *Chest* 119:1469–1475
- Cao Y, Tsien CI, Shen Z et al (2005) Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. *J Clin Oncol* 23:4127–4136

- Christodoulou C, Bafaloukos D, Kosmidis P et al (2001) Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. *Ann Oncol* 12:249–254
- Flannery TW, Suntharalingam M, Regine WF et al (2008) Long-term survival in patients with synchronous, solitary brain metastasis from non-small-cell lung cancer treated with radiosurgery. *Int J Radiat Oncol Biol Phys* 72:19–23
- Fleckenstein K, Hof H, Lohr F et al (2004) Prognostic factors for brain metastases after whole brain radiotherapy. *Strahlenther Onkol* 180:268–273
- Gaspar L, Scott C, Rotman M et al (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. *Int J Radiat Oncol Biol Phys* 37:745–751
- Gaspar LE, Mehta MP, Patchell RA et al (2010) The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 96:17–32
- Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. *J Clin Oncol* 25:2306–2312
- Hashimoto K, Narita Y, Miyakita Y et al (2011) Comparison of clinical outcomes of surgery followed by local brain radiotherapy and surgery followed by whole brain radiotherapy in patients with single brain metastasis: single-center retrospective analysis. *Int J Radiat Oncol Biol Phys* 81:e475–e480
- Hu C, Chang EL, Hassenbusch SJ III et al (2006) Nonsmall cell lung cancer presenting with synchronous solitary brain metastasis. *Cancer* 106:1998–2004
- Katayama T, Shimizu J, Suda K et al (2009) Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib. *J Thorac Oncol* 4:1415–1419
- Kim JE, Lee DH, Choi Y et al (2009) Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. *Lung Cancer* 65:351–354
- Korfel A, Oehm C, von Pawel J et al (2002) Response to topotecan of symptomatic brain metastases of small-cell lung cancer also after whole-brain irradiation. A multicentre phase II study. *Eur J Cancer* 38:1724–1729
- Lagerwaard FJ, Levendag PC, Nowak P et al (1999) Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. *Int J Radiat Oncol Biol Phys* 43:795–803
- Mehta MP, Paleologos NA, Mikkelsen T et al (2010) The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 96:71–83
- Narita Y, Shibui S (2009) Strategy of surgery and radiation therapy for brain metastases. *Int J Clin Oncol* 14:275–280
- Neuhaus T, Ko Y, Muller RP, Grabenbauer GG et al (2009) A phase III trial of topotecan and whole brain radiation therapy for patients with CNS-metastases due to lung cancer. *Br J Cancer* 100:291–297
- Ostermann S, Csajka C, Buclin T et al (2004) Plasma and cerebrospinal fluid pharmacokinetics of temozolomide in malignant glioma patients. *Clin Cancer Res* 10:3728–3736
- Park YH, Park MJ, Ji SH et al (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-over-expressing breast cancer patients. *Br J Cancer* 100:894–900
- Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 322:494–500
- Robinet G, Thomas P, Breton JL et al (2001) Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95–1. *Ann Oncol* 12:59–67
- Sánchez Cos J, Sojo González MA et al (2009) Non-small cell lung cancer and silent brain metastasis. Survival and prognostic factors. *Lung Cancer* 63:140–145
- Siena S, Crinò L, Danova M et al (2010) Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study. *Ann Oncol* 21:655–661
- Sneed PK, Lamborn KR, Forstner JM et al (1999) Radiosurgery for brain metastases: is whole brain radiotherapy necessary? *Int J Radiat Oncol Biol Phys* 43:949–958
- Soffiotti R, Ruda R, Mutani R (2002) Management of brain metastasis. *J Neurol* 249:1357–1369
- Swinson BM, William FA (2008) Linear accelerator stereotactic radiosurgery for metastatic brain tumors: 17 years of experience at the University of Florida. *Neurosurgery* 62:1018–1032
- Tsao MN, Lloyd NS, Wong RKS et al (2005) Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. *Cancer Treat Rev* 31:256–273
- Vecht CJ, Haaxma-Reiche H, Noordijk EM et al (1993) Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery. *Ann Neurol* 33:583–590
- Walbert T, Gilbert MR (2009) The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. *Int J Clin Oncol* 14:299–306
- Weissman DE (1988) Glucocorticoid treatment for brain metastases and epidural spinal cord compression: a review. *J Clin Oncol* 6:543–551
- Wilson CM, Gaber MW, Sabek OM et al (2009) Radiation-induced astrogliosis and blood-brain barrier damage can be abrogated using anti-TNF treatment. *Int J Radiat Oncol Biol Phys* 74:934–941
- Wu C, Li YL, Wang ZM et al (2007) Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. *Lung Cancer* 57:359–364
- Yuan H, Gaber MW, Boyd K et al (2006) Effects of fractionated radiation on the brain vasculature in a murine model: blood-brain barrier permeability, astrocyte proliferation, and ultra-structural changes. *Int J Radiat Oncol Biol Phys* 66:860–866

